Clinical features and treatment of drug fever caused by anti-tuberculosis drugs

被引:9
|
作者
Fang, Yong [1 ]
Xiao, Heping [1 ]
Tang, Shenjie [1 ]
Liang, Li [1 ]
Sha, Wei [1 ]
Fang, Yuanyuan [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Key Lab TB, TB Ctr Diag & Treatment,Shanghai Pulm Hosp, Shanghai 200433, Peoples R China
来源
CLINICAL RESPIRATORY JOURNAL | 2016年 / 10卷 / 04期
关键词
adverse reaction; anti-tuberculosis drugs; drug fever; treatment;
D O I
10.1111/crj.12242
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and AimsTuberculosis is a major global health problem. However, anti-tuberculosis drug treatment has many adverse effects, such as drug-caused fever. The aim of this study was to investigate the clinical features and treatments of anti-tuberculosis drugs-induced fever. MethodsA total of 78 inpatients and outpatients with pulmonary tuberculosis accompanied by drug fever during the anti-tuberculosis treatment were analysed retrospectively from April 2006 to March 2013. ResultsAmong the anti-tuberculosis drugs that caused the drug fever, rifampicin was the most common one, followed by para-aminosalicylic and pyrazinamide. The symptoms occurred within 2 months after treatment, mainly in the 1-3 weeks, and the main symptom was high fever with body temperature above 39 degrees C. The accompanying symptoms include rash, chills, headache, stuffy nose, runny nose, nausea, vomiting and joint pain. Routine blood examination found that eosinophilia increased in 15 cases and decreased in another 15. Among 63 patients who underwent liver function tests, there were 10 cases of abnormal function and 4 cases of liver damage. When the drug fever was suspected, the measure of withdrawal was taken first. All the suspected drugs were withdrawn in 59 cases, while gradual withdrawal was conducted in 19 cases. Patients with complications were first treated in accordance with the principles of complications treatment and then were gradually given some drugs after recovery. The patients without complications were gradually given some drugs after the body temperature was back to normal. ConclusionDrug fever is an allergic reaction, the resolution of which depends on whether it was accompanied by liver damage and/or rash or not.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 50 条
  • [41] Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco
    Mariam El Hamdouni
    Samir Ahid
    Jamal Eddine Bourkadi
    Jouda Benamor
    Mohammed Hassar
    Yahia Cherrah
    Infection, 2020, 48 : 43 - 50
  • [42] In vitro anti-tuberculosis activity of azole drugs against Mycobacterium tuberculosis clinical isolates
    Imperiale, Belen R.
    Cataldi, Angel A.
    Morcillo, Nora S.
    REVISTA ARGENTINA DE MICROBIOLOGIA, 2017, 49 (04): : 332 - 338
  • [43] Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
    Xu, Lin
    Chen, Jinou
    Innes, Anh L.
    Li, Ling
    Chiang, Chen-Yuan
    PLOS ONE, 2017, 12 (10):
  • [44] NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis
    Yuliwulandari, Rika
    Susilowati, Retno Wilujeng
    Wicaksono, Britanto Dani
    Viyati, Kencono
    Prayuni, Kinasih
    Razari, Intan
    Kristin, Erna
    Syafrizal
    Subagyo
    Diana, Eva Sri
    Setiawati, Suci
    Ariyani, Aziza
    Mahasirimongkol, Surakameth
    Yanai, Hideki
    Mushiroda, Taisei
    Tokunaga, Katsushi
    JOURNAL OF HUMAN GENETICS, 2016, 61 (06) : 533 - 537
  • [45] NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis
    Rika Yuliwulandari
    Retno Wilujeng Susilowati
    Britanto Dani Wicaksono
    Kencono Viyati
    Kinasih Prayuni
    Intan Razari
    Erna Kristin
    Eva Syafrizal
    Suci Subagyo
    Aziza Sri Diana
    Surakameth Setiawati
    Hideki Ariyani
    Taisei Mahasirimongkol
    Katsushi Yanai
    Journal of Human Genetics, 2016, 61 : 533 - 537
  • [46] New anti-tuberculosis drugs in clinical trials with novel mechanisms of action
    Rivers, Emma C.
    Mancera, Ricardo L.
    DRUG DISCOVERY TODAY, 2008, 13 (23-24) : 1090 - 1098
  • [47] Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco
    El Hamdouni, Mariam
    Ahid, Samir
    Bourkadi, Jamal Eddine
    Benamor, Jouda
    Hassar, Mohammed
    Cherrah, Yahia
    INFECTION, 2020, 48 (01) : 43 - 50
  • [48] Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring
    Verbeeck, Roger K.
    Guenther, Gunar
    Kibuule, Dan
    Hunter, Christian
    Rennie, Tim W.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (08) : 905 - 916
  • [49] Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring
    Roger K. Verbeeck
    Gunar Günther
    Dan Kibuule
    Christian Hunter
    Tim W. Rennie
    European Journal of Clinical Pharmacology, 2016, 72 : 905 - 916
  • [50] Anti-tuberculosis treatment and infliximab
    Wallis, RS
    RESPIRATORY MEDICINE, 2005, 99 (12) : 1620 - 1622